癌症免疫治療市場：依治療類型、給藥途徑、癌症類型、通路和地區分類

2025 年全球癌症免疫治療市場規模估計為 1,584.2 億美元，預計到 2032 年將達到 3,570.7 億美元，2025 年至 2032 年的複合年成長率為 12.3%。

數字。 2025 年各地區癌症免疫治療市場佔有率（%）

癌症免疫療法是一種利用人體免疫系統對抗癌症的癌症治療方法。這是一種創新方法，利用免疫系統的力量並對其進行修改以增強人體對抗癌症的天然防禦能力。癌症免疫療法包括單株抗體、查核點抑制劑、白細胞介素抑制劑和治療性癌症疫苗等治療方法。最近的科學進展使人們對癌細胞和免疫系統之間的複雜相互作用有了更深入的了解，從而引起了人們越來越濃厚的興趣。癌症免疫療法是一種新的治療模式，有可能在未來大幅改變癌症治療方法。

市場動態：

全球癌症免疫治療市場的成長受到多種因素的推動，例如全球癌症發病率不斷上升、對有效標靶治療的需求不斷增加，以及與傳統治療方法相比，癌症免疫治療具有更高的治療成功率。癌症仍然是死亡的主要原因之一，預計在不久的將來全球癌症負擔將大幅增加。這是免疫療法被採用的主要動力。生物技術的進步和我們對癌症免疫學的理解為開發新型免疫療法和改善患者治療效果鋪平了道路。然而，免疫療法藥物的高成本、對專門基礎設施和醫療保健人力的需求以及與免疫療法相關的安全問題是限制市場成長的一些挑戰。該領域的積極研究和開發、針對新癌症類型的研發以及正在進行的臨床試驗有可能為市場參與者提供成長機會。

本研究的主要特點

• 本報告對全球癌症免疫治療市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 該報告根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球免疫腫瘤學市場的主要企業。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球癌症免疫療法市場報告涵蓋該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過用於分析全球免疫腫瘤學市場的各種策略矩陣來促進他們的決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 市場機會
• 影響分析
• 市場趨勢
• 最新動態
• 收購和合作場景
• 技術概述
• 監管情景
• 定價分析
• PEST分析

第 4 章全球癌症免疫治療市場-冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

5. 2020 年至 2032 年全球癌症免疫療法市場（按治療類型分類）（十億美元）

• 免疫查核點抑制劑
• 疫苗
• 預防疫苗
• 治療性疫苗
• 過繼細胞治療
• 腫瘤浸潤淋巴細胞 (TIL) 治療
• CAR-T 細胞療法
• 工程 T 細胞受體 (TCR) 療法
• 自然殺手（NK）細胞療法
• 免疫系統調節劑
• 干擾素
• 免疫調節藥物 (IMiD)
• 白細胞介素
• 單株抗體
• 裸露的單株抗體
• 結合單株抗體
• 雙特異性單株抗體
• 溶瘤病毒治療

6. 2020 年至 2032 年按給藥途徑分類的全球癌症免疫治療市場（十億美元）

• 皮下
• 口服
• 肌肉注射
• 靜脈注射 (IV)
• 其他

7. 2020 年至 2032 年全球癌症免疫治療市場（按癌症類型分類）（十億美元）

• 淋巴瘤
• 乳癌
• 大腸直腸癌
• 膀胱癌
• 皮膚癌
• 肺癌
• 腎癌
• 其他

8. 2020 年至 2032 年全球癌症免疫治療市場按通路分類（十億美元）

• 醫院藥房
• 零售藥局
• 網路藥局

9. 2020 年至 2032 年全球癌症免疫治療市場（按地區分類）（十億美元）

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區

Global Cancer Immunotherapy Market is estimated to be valued at USD 158.42 Bn in 2025 and is expected to reach USD 357.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.

Figure. Cancer Immunotherapy Market Share (%), By Region 2025

Cancer immunotherapy is a type of cancer treatment that utilizes the body's own immune system to fight against cancer. It is an innovative approach that harnesses the power of the immune system and modifies it to enhance the body's natural defenses against cancer. Cancer immunotherapy comprises therapies like monoclonal antibodies, checkpoint inhibitors, interleukin inhibitors, therapeutic cancer vaccines and others. It is gaining prominence as recent scientific breakthroughs have improved understanding of the complex interaction between tumor cells and the immune system. Cancer immunotherapy represents a novel treatment paradigm that has the potential to transform the way cancer is treated in the future.

Market Dynamics:

Global cancer immunotherapy market growth is driven by factors such as increasing prevalence of cancer worldwide, rising demand for effective targeted therapies, and higher treatment success rates associated with cancer immunotherapy as compared to conventional treatment modalities. Cancer remains one of the leading causes of mortality and the global burden of cancer is expected to rise significantly in the near future. This is providing a major boost to immunotherapy adoption. Advancements in biotechnology along with better understanding of cancer immunology have led to the development of novel immunotherapies, which are paving the way for improved patient outcomes. However, high costs associated with immunotherapy drugs, need for specialized infrastructure and healthcare personnel, and safety concerns related to immunotherapy are some of the challenges restraining the market growth. Active R&D in this field, targeting new cancer types, and ongoing clinical trials hold potential to provide growth opportunities for market players.

Key Features of the Study:

• This report provides in-depth analysis of the global cancer immunotherapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cancer immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., Fate Therapeutics., AstraZeneca, Amgen Inc., GSK plc., Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., BioNTech SE, Cellectis, immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., Gritstone bio, and Incyte.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cancer immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer immunotherapy market.

Detailed Segmentation-

• Therapy Type:
  • Immune checkpoint inhibitors
  • Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
  • Adoptive Cell Therapies
  • Tumor-infiltrating lymphocyte (TIL) therapy
  • CAR T-cell therapy
  • Engineered T-cell receptor (TCR) therapy
  • Natural killer (NK) cell therapy
  • Immune System Modulators
  • Interferons
  • Immunomodulators (IMiDs)
  • Interleukins
  • Monoclonal antibodies
  • Naked monoclonal antibodies
  • Conjugated monoclonal antibodies
  • Bispecific monoclonal antibodies
  • Oncolytic Virus Therapy
• Route of Administration:
  • Subcutaneous
  • Oral
  • Intramuscular
  • Intravenous (IV)
  • Others
• Cancer Type:
  • Lymphoma
  • Breast Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Skin Cancer
  • Lung Cancer
  • Kidney Cancer
  • Others
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics.
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapy Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Cancer Immunotherapy Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Cancer Immunotherapy Market, By Therapy Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Immune checkpoint inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Preventive Vaccines
• Therapeutic Vaccines
• Adoptive Cell Therapies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Tumor-infiltrating lymphocyte (TIL) therapy
• CAR T-cell therapy
• Engineered T-cell receptor (TCR) therapy
• Natural killer (NK) cell therapy
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Interferons
• Immunomodulators (IMiDs)
• Interleukins
• Monoclonal antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Naked monoclonal antibodies
• Conjugated monoclonal antibodies
• Bispecific monoclonal antibodies
• Oncolytic Virus Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Cancer Immunotherapy Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intramuscular
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous (IV)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cancer Immunotherapy Market, By Cancer Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Skin Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Kidney Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Cancer Immunotherapy Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Cancer Immunotherapy Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

• Company Profiles
  • Gilead Sciences, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact